GeneSight Testing for ADHD Medications: Not Recommended

Introduction to ADHD Medication Selection

The American Academy of Pediatrics explicitly states that pharmacogenetic tools, including GeneSight, are not recommended for ADHD medication management due to critical evidence gaps 1, 2, 3, 4

Genetic variants have not been consistently studied with respect to ADHD symptom improvement or functional impairment 1, 2, 3
Study findings are inconsistent across different investigations of the same genetic markers 1, 2, 3
Effect sizes are insufficient to ensure meaningful clinical utility even when associations are found 1, 2, 3

For any pharmacogenetic tool to be clinically recommended for ADHD, studies must demonstrate consistent, replicated associations between genetic variants and medication response to ADHD treatments 1, 2, 3
Changed clinical decision-making that improves outcomes, reduces costs, or decreases treatment burden is required 1, 2, 3
Acceptable operating characteristics, including demonstrated sensitivity, specificity, and reliability, must be shown 1, 2, 3

These tests typically cost thousands of dollars and are usually not covered by insurance 1, 2, 3, 4, 5, 6
The financial burden provides no return in improved ADHD outcomes based on current evidence 1, 2, 3

The evidence-based approach for ADHD medication management involves starting with FDA-approved stimulants (methylphenidate or amphetamine formulations) with an effect size of 1.0 1, 3, 4
Individual response is idiosyncratic: approximately 40% respond to both methylphenidate and amphetamine, while 40% respond to only one 1, 3, 4, 6
Clinical trial determines the best medication: systematically try different stimulants if the initial choice is ineffective 1, 3, 4
Non-stimulant alternatives (atomoxetine, extended-release guanfacine, extended-release clonidine) have effect sizes around 0.7 and serve as second-line options 1, 3, 4